DIRS.INFO The most relevant business & tech news

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ AI helped crack COVID, and now 83% of Moderna employees use ChatGPT daily, says chief brand officer Kate Cronin
▼ + stars: | 2024-06-24 | by ( Julia Hood | ) www.businessinsider.com time to read: 1 min

Link icon An image of a chain link. It symobilizes a website link url. Link icon An image of a chain link. Copy LinkTwitter LinkedIn icon LinkedIn Link icon An image of a chain link. Twitter LinkedIn icon LinkedIn Link icon An image of a chain link.

☆ CNBC Daily Open: Apple upgrades Siri with AI
▼ + stars: | 2024-06-11 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Apple IntelligenceShares of Apple fell 1.9% after the iPhone maker delivered its long-awaited AI strategy. Siri will get an upgrade with Apple Intelligence and access to OpenAI's ChatGPT. Investors are concerned Apple had fallen behind its rivals, Microsoft and Google, in the race to deliver AI services and tools.

Persons: Goldman Sachs, Siri, Apple, Elon Musk's, Chris Ailman, CNBC's, Ailman, CalSTRS, Elliott, Moderna, Tesla, Elon, Bernstein Organizations: CNBC, Nasdaq, Technology, Nvidia, Meta, Microsoft, Dow Jones, Apple Intelligence, Apple, Investors, Google, California State Teachers, Elliott, Southwest, Elliott Management, Southwest Airlines, Boeing, Pfizer, Novavax Locations: U.S

☆ 3 actions extraordinary people take to achieve what seems impossible, from the co-founder of Moderna
▼ + stars: | 2024-06-11 | by ( Alex Koller | ) www.cnbc.com time to read: +3 min

If you need to tackle an improbable challenge, the right mindset — "a special kind of optimism" — can help, according to Moderna co-founder and chairman Noubar Afeyan. Specifically, Afeyan — who has an estimated net worth of $1.5 billion, according to Forbes — said that "extraordinary change agents" take three actions to achieve what seems impossible:They imagine. Imagination plays a crucial role "in accomplishing impossible missions," Afeyan said: You typically need to think creatively to come up with new, original ideas. But ask yourself one central question: Why do we expect extraordinary results from reasonable people doing reasonable things?" "You need to leave your comfort zone, to think in new ways, to acclimate to the unfamiliar and embrace uncertainty."

Persons: Noubar Afeyan, he's, Afeyan —, Forbes —, Afeyan, Allison Butler, Butler Organizations: Moderna, Massachusetts Institute of Technology, MIT, Sloan School of Management, Bryant University, CNBC Locations: Lebanon, Canada, Massachusetts, Cambodia, California, Cambridge, acclimate

☆ 5 things to know before the stock market opens
▼ + stars: | 2024-06-11 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

At Apple's annual Worldwide Developers Conference on Monday, the company unveiled "Apple Intelligence" – its long-awaited AI software. Apple CEO Tim Cook stressed privacy and personalization with the system, moving beyond AI into "personal intelligence." Siri will also be getting some upgrades with Apple Intelligence, and Apple announced that Siri will also be able to tap into ChatGPT when needed through the company's partnership with OpenAI. The activist hedge fund has taken a $1.9 billion stake in Southwest Airlines , which makes it one of the airline's biggest investors. This follows a number of other stakes the firm has built within the past two months, such as a $2.5 billion stake in Texas Instruments, a $2 billion stake in SoftBank and a $1 billion stake in Anglo American.

Persons: Tim Cook, John Giannandrea, Craig Federighi, Nic Coury, Siri, Elliott, Gary Hershorn, it's, Bob Jordan, Gary Kelly, Fred Tanneau, Stephane Bancel, Francis Scott Key, Michael A Organizations: Nasdaq, Dow Jones, Nvidia, Apple, Developers, AFP, Getty, Apple Intelligence, OpenAI, Max, Southwest Airlines, Hollywood International Airport, Corbis, Elliott Management, Texas, Moderna, Afp, Francis Scott Key Bridge, McCoy, Washington Post Locations: Cupertino , California, Fort Lauderdale, Fort Lauderdale , Florida, SoftBank, U.S, Baltimore

☆ Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. Moderna's messenger RNA combination shot, called mRNA-1083, is made up of both the company's vaccine candidate for seasonal influenza and a newer, "next-generation" version of its Covid shot. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's currently licensed Covid shot, Spikevax, in one group of patients ages 65 and above. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV. Meanwhile, Pfizer and BioNTech also are studying a vaccine that targets both Covid and the flu in a late-stage trial.

Persons: Stephane Bancel, Novavax, Bancel, Moderna, BioNTech Organizations: Pfizer, Novavax, Moderna, Covid Locations: U.S

☆ Covid-flu combination vaccine shows positive results in late-stage trial, Moderna says
▼ + stars: | 2024-06-10 | by ( Jen Christensen | ) edition.cnn.com time to read: +5 min

CNN —There could be a combined Covid-19 and flu shot in our future, although it won’t be ready for this year’s flu season. On Monday, vaccine maker Moderna announced positive late-stage trial results for its Covid/flu combination vaccine it calls mRNA-1083. Other companies have been testing a combined Covid-flu vaccine, but Moderna is the first to announce positive late-stage trial results. The trial studied the vaccine in two different age groups with about 4,000 adults in each age category. Few people got the latest Covid shot, studies show.

Persons: ”, Francesca Ceddia, ” Ceddia, Covid, Spikevax, Moderna, Sue Peschin, Dr, Sanjay Gupta, Peschin, ” Peschin, “ Organizations: CNN, Moderna, Public, US Centers for Disease Control, Food, Covid, FDA, Alliance for Aging Research, CNN Health, CDC Locations: United States

☆ Moderna’s combination flu & Covid vaccine is more effective than existing shots in late-stage trial
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna’s combination flu & Covid vaccine is more effective than existing shots in late-stage trialModerna CEO Stephane Bancel joins 'Squawk Box' to discuss the data from its phase three trial of a combination flu and Covid-19 vaccine, the company's vaccine pipeline outlook, and more.

Persons: Stephane Bancel

☆ FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
▼ + stars: | 2024-06-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.

Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan

☆ Nobel Prize-winning chemist Thomas R. Cech on ‘The Catalyst’ and the future of RNA
▼ + stars: | 2024-06-05 | by ( Saira Mueller | ) edition.cnn.com time to read: +13 min

“We saw that with the mRNA (messenger RNA) vaccines that it can be a good messenger,” says Cech. The Catalyst by Thomas R. Cech W W NortonYou mentioned in “The Catalyst” that research on RNA has been around since the ‘50s. What is something that most people get wrong about mRNA vaccines, such as the Covid-19 ones? Thomas R. Cech in a lab in 1984, five years before he won the Nobel Prize in Chemistry. How does this apply to DNA, RNA, mRNA and CRISPR?

Persons: you’re, ”, Thomas R, Cech, ” Cech, Sidney Altman, he’s, Norton, It’s, Thomas R . Cech, — Organizations: CNN, Pfizer, DNA, University of Colorado, Denver Post, Rotary Clubs, Lions Locations: Moderna, University of Colorado , Boulder, Boulder , Colorado, China, Cambridge , Massachusetts, United States, Germany

☆ Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
▼ + stars: | 2024-06-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.

Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna

☆ CNBC Daily Open: Opec extends cuts, Nvidia showcases new chip
▼ + stars: | 2024-06-03 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. OPEC+ extends cutsOPEC and it allies agreed to extend official crude production cuts into 2025 amid lackluster demand. Saudi Arabia's energy minister Prince Abdulaziz bin Salman said OPEC+ wants concrete rate cuts before factoring in the potential impact on energy demand. New AI chip RubinNvidia unveiled its next generation artificial intelligence chip, Rubin, a mere three months after launching its Blackwell model.

Persons: Prince Abdulaziz bin Salman, Rubin, Blackwell, Dow, UnitedHealth, Bill Ackman, It's, Michael Khouw Organizations: CNBC, Saudi Aramco, Rubin Nvidia, AMD, Intel, Microsoft, Google, Dow Jones, Federal, Dow, Nasdaq, Nvidia, Tesla, Pershing, Moderna, Drug Administration, GSK, Pfizer Locations: OPEC, Saudi Arabia, Russia, Saudi, U.S, Moderna

☆ FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
▼ + stars: | 2024-05-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial virus for adults ages 60 and above, the company's second-ever product to enter the U.S. market. The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The company's shot is also the only RSV vaccine to be available in a pre-filled syringe, which is designed to make it easier to administer to patients. An advisory panel to the CDC will vote in June on recommendations for the use and intended population of Moderna's shot. Moderna's full-year 2024 sales guidance of roughly $4 billion includes revenue from its RSV vaccine.

Persons: Moderna's, Stéphane Bancel Organizations: Drug Administration, Moderna, Centers for Disease Control, CDC, GSK, Pfizer Locations: U.S

☆ Moderna and this solar name are among the most overbought stocks after a record-setting week
▼ + stars: | 2024-05-24 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

It may be time for investors to trim positions in overbought names after the stock market reached record levels this week. Certain stocks this week became overbought, based on their 14-day relative strength index, or RSI. Here are the most overbought names in the S & P 500 this week: Moderna was the most overbought stock in the S & P 500, scoring an RSI of about 86.5. Analysts think shares, which have rallied about 28% this year, could peel back roughly 8%. Other oversold stocks include SLB , J.B. Hunt and Molson Coors .

Persons: LSEG, Jon Windham, Johnson, Ulta, Hunt Organizations: Dow Jones Industrial, Nasdaq, Nvidia, Moderna, UBS, Johnson Controls, Bloomberg, Elliott Investment Management, Johnson, Barclays, Deutsche Bank, Jefferies, Molson Coors Locations: U.S, oversold, J.B

☆ Here's how U.S. health officials are responding to bird flu in humans after second case
▼ + stars: | 2024-05-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Brandon Bell | Getty ImagesU.S. health officials are monitoring and preparing to combat bird flu in humans, even as they stress that the risk to the general public remains low. An Australian child was also recently infected with bird flu, the country announced on Tuesday. In rare cases, bird flu viruses spread to humans and can cause mild to severe symptoms that can require hospitalization. The Food and Drug Administration would need to approve bird flu vaccines before they roll out. Potential mRNA shotsU.S. health officials are also in talks with messenger RNA vaccine makers about potential bird flu shots for humans.

Persons: Brandon Bell, Andrew Pekosz, Pekosz, Peter Chin, That's, Hong Organizations: Getty, Disease Control, U.S ., Human Services Department, CNBC, Johns Hopkins Bloomberg School of Public Health, CDC, HHS, NBC News, UCSF Health, Drug Administration, FDA, Pfizer, Moderna Locations: Quemado , Texas, Michigan, Australian, U.S

☆ Lightning Round: Moderna, Comfort System USA, Sunoco, Celestica and AMC
▼ + stars: | 2024-05-24 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Moderna, Comfort System USA, Sunoco, Celestica and AMCCNBC's Jim Cramer breaks down a variety of stock during the 'Mad Money' Lightning Round.

Persons: Jim Cramer Organizations: Comfort System, AMC

☆ Cramer's Lighting Round: Sell AMC
▼ + stars: | 2024-05-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Moderna's year-to-date stock performance. Stock Chart Icon Stock chart icon Comfort Systems' year-to-date stock performance. Stock Chart Icon Stock chart icon Sunoco's year-to-date stock performance. Stock Chart Icon Stock chart icon Celestica's year-to-date stock performance. Stock Chart Icon Stock chart icon AMC Entertainment's year-to-date stock performance.

Organizations: Comfort Systems, AMC, AMC Entertainment, Systems, Inspire Medical

☆ Stocks making the biggest moves midday: Target, Urban Outfitters, Tesla, Shopify and more
▼ + stars: | 2024-05-22 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Urban Outfitters — The clothing retailer slid 4.6% despite posting a fiscal first-quarter beat, after trading higher before Tuesday's opening bell. Urban Outfitters reported adjusted earnings of 69 cents per share, higher than the 52 cents per share analysts polled by LSEG had expected. First Solar — Shares surged more than 18% in midday trading. Other alt energy stocks also surged, in part owing to enthusiasm that AI will lift power demand. Bloom Energy surged 18%; Sunnova Energy added 14%; and Enphase Energy , Fluence Energy and Sunrun were all up 10%.

Persons: Goldman Sachs, LSEG, —, Alex Harring, Lisa Kailai Han, Jeff Greenberg Organizations: Goldman, Urban Outfitters, Garmin, Bank of America, —, Toll, Citi, Tesla, Elon, Bloomberg, UBS, Bloom Energy, Sunnova Energy, Enphase Energy, Fluence Energy, Sonoma, Universal, Getty Locations: Massachusetts, Europe, FactSet, Miami Beach , Florida

☆ The stock market gets nailed by the Fed, again. Plus, Starbucks' quiet comeback
▼ + stars: | 2024-05-22 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

One Club stock standout Wednesday was off-price retailer TJX after the T.J. Maxx, Marshalls and HomeGoods owner's solid quarter. The recent action in the Club stock has us wondering if a big buyer is lurking out there. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Ralph Lauren, Jim Cramer's, Jim Organizations: CNBC, Federal, Club, Marshalls, Nvidia, Moderna, Tech, Enphase Energy, Corp, BJ's Wholesale, Jim Cramer's Charitable Locations: Maxx

☆ Final Trades: Moderna, Palantir, Oracle and Bank of America
▼ + stars: | 2024-05-21 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Moderna, Palantir, Oracle and Bank of AmericaThe Investment Committee gives you their top stocks to watch for the second half.

Organizations: Moderna, Palantir, Oracle, Bank of America, Investment

☆ Lightning Round: Hertz is too cheap right now, says Jim Cramer
▼ + stars: | 2024-05-14 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Hertz is too cheap right now, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Moderna, Modine Manufacturing, AMETEK, Hertz, Palantir and more.

Persons: Hertz, Jim Cramer Organizations: Moderna, Modine

☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
▼ + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."

Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —

☆ Cramer's Lightning Round: 'I'm a believer' in Moderna
▼ + stars: | 2024-05-14 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

MindMed : "I like MindMed...Anything that makes it so that there's ways to be able to get rid of pain and do good without getting people hooked, I am all in on. Doesn't necessarily mean it will make a lot of money, I don't care. I think that people have to recognize this is an unmet need, and it will make money in the end."

☆ MDMA therapy could be legalized by summer. Why are so many advocates sounding the alarm?
▼ + stars: | 2024-05-13 | by ( Anna Silman | ) www.businessinsider.com time to read: +52 min

Last summer, thousands of tie-dyed Burners and Patagonia-clad tech founders converged on the MAPS Psychedelic Science conference in Denver. The experience "broke the spell of this trauma, and she was able to rebuild her life," Doblin told The Guardian . The video team's job was to store recordings of every MDMA therapy session performed in the clinical trials. Grof believes in something called an "inner healing intelligence," an innate capacity for self-healing that psychedelic therapy helps unleash. Another time, a patient who had come to an MDMA therapy session later acknowledged they had been under the influence of LSD during treatment.

Persons: Jaden Smith, Aaron Rodgers, bro, Andrew Huberman, Rick Doblin, Doblin, mainstreaming psychedelics, influencers, Johnson, Elizabeth Nielson, Aubrey Marcus, ayahuasca, Matthew Stockman, Helena —, Timothy Leary, —, Hitler, Stanislav Grof, zombified, Brad Burge, Michael Mithoefer, Annie Mithoefer, Oprah, Sen, Joe Biden, MDMA's neurotoxicity, they'd, Albert Hofmann, David Bronner, Dr, Joe's, Bronner, Bronner's, Richard Rockefeller, John D, Rockefeller Jr, Rockefeller, Neşe, Johns Hopkins, who's, Devenot, Rick Friedman, Betty Aldworth, MAPS's multimillionaire, Tim Ferriss, Cody Swift, Zendo, Aldworth, Erica Siegal, Seth Whitelaw, Amy Emerson, JULIE JAMMOT, Ifetayo Harvey, Harvey, Lauren Unger, Unger, Casey Hardison, Harvey didn't, Hardison, Doblin's, Baylee Ybarra Gatlin, Gatlin, negligently, There's, Michael Pollan's, Steve Jurvetson, Elon Musk's who's, Genevieve, Steve Cohen, Alexandra, Mark Zuckerberg's, Dustin Moskovitz, Cari, Gwyneth Paltrow, Paltrow, Sergey Brin, Joe Green, Green, Zuckerberg, Genevieve Jurvetson, Michael Pollan, Jonathan Lubecky, he'd, Rebekah, Robert Mercer, Elizabeth Koch, Charles Koch, Rachel Nuwer, Koch, she'd, MAPS's, Elizabeth Crystal, Joe Rogan, didn't, Jesus Christ, Crystal, Meaghan Buisson, Richard Yensen, Donna, Yensen, Buisson, weren't, Robert, Rebekah Mercer, Sean Zanni, Grof, They've, Kayla Greenstien, it's, George Sarlo who'd, Vicky Dulai, Sarlo's, Dulai, Gul Dolen, Michael Mullette, who'd, Marla Aufmuth, Mullette, Lily Kay Ross, David Nickles, Ross, Greenstien, Rick, Lenny Ignelzi, biostatisticians, Lykos, Peter Thiel, Kara Swisher, Kris Lotlikar, Federico Menapace, Mo Septimus, Handout, Monnica, Williams, Lotlikar, Henry Elkus, Helena ., Elkus, Emerson, ICER Organizations: Science, New York Jets, rockstar, Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics, and Drug Administration, FDA, Business, Florida's New College, Jewish Telegraphic Agency, Sarasota Herald, Tribune, New College, Guardian, Drug, Harvard's Kennedy School of Government, eBay, Nevada, Doblin, Pentagon, Department of Veterans Affairs, Department of Defense, Staff, Corporation, PBC, pharma, New Yorker, New York Mets, Bloomberg, CBS, Breitbart, CBC News, BI, Porsche, Santa Cruz, New York Times, longtime, Mullette Corporation, New York, Health Canada, Compass, Sciences, Psychedelic Science, Whole Foods, McKinsey, Big Pharma, Vine Ventures, Lucid, Street Journal, Investments, Gawker, Publicly, PBC alums, Numinus, US Army Locations: Patagonia, Denver, Harvard, Colorado, Skokie , Illinois, Ireland, Czech, Sarasota, Arcturus, Florida, Swiss, Vietnam, Washington, Santa Cruz, Chicago, California, Iraq, British Columbia, New York, Hawaii, Santa, Nature, Moderna, Europe, Helena, Yale, Australia, Canada, Israel, Ukraine, ICER, . Upper

☆ Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
▼ + stars: | 2024-05-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company's Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. Part of the deal allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products. Novavax is also entitled to royalty payments on Sanofi's sales of its Covid vaccine and combination shots targeting coronavirus and the flu. Under the deal, Sanofi will also take a less than 5% stake in Novavax.

Persons: Novavax, Sanofi, John Jacobs, Jacobs Organizations: Dutch Health Service Organization, French, CNBC, Health, Pfizer, Moderna, Sanofi Locations: The Hague, Netherlands, Novavax

Search resuls for: "Modernă"

25 mentions found